These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 22008803)

  • 1. UK needs vaccine to protect against HPV types causing recurrent respiratory papillomatosis.
    Rothera MP; Albert DM; Hughes OR
    BMJ; 2011 Oct; 343():d6672. PubMed ID: 22008803
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparing bivalent and quadrivalent HPV vaccines.
    Verheijen RH
    BMJ; 2011 Sep; 343():d5720. PubMed ID: 21951757
    [No Abstract]   [Full Text] [Related]  

  • 3. HPV vaccine prices in Italy.
    Garattini L; van de Vooren K; Casadei G
    BMJ; 2011 Oct; 343():d6668. PubMed ID: 22008802
    [No Abstract]   [Full Text] [Related]  

  • 4. Changing face of HPV related cancer in the UK.
    Schache AG; Simcock R; Gilbert DC; Shaw RJ
    BMJ; 2011 Oct; 343():d6675. PubMed ID: 22008804
    [No Abstract]   [Full Text] [Related]  

  • 5. Comparing bivalent and quadrivalent human papillomavirus vaccines: economic evaluation based on transmission model.
    Jit M; Chapman R; Hughes O; Choi YH
    BMJ; 2011 Sep; 343():d5775. PubMed ID: 21951758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and a human papillomavirus (HPV)-6/11/16/18 vaccine in Canada.
    Kohli M; Lawrence D; Haig J; Anonychuk A; Demarteau N
    BMC Public Health; 2012 Oct; 12():872. PubMed ID: 23061913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HPV vaccine strategies: the cost of HPV and the choice of vaccine.
    Morris SR
    Sex Transm Infect; 2009 Sep; 85(5):315-6. PubMed ID: 19773455
    [No Abstract]   [Full Text] [Related]  

  • 8. A brief history of economic evaluation for human papillomavirus vaccination policy.
    Beutels P; Jit M
    Sex Health; 2010 Sep; 7(3):352-8. PubMed ID: 20719227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccines for human papillomavirus infection: a critical analysis.
    Nath AK; Thappa DM
    Indian J Dermatol Venereol Leprol; 2009; 75(3):245-53; quiz 254. PubMed ID: 19439876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health and economic implications of HPV vaccination in the United States.
    Kim JJ; Goldie SJ
    N Engl J Med; 2008 Aug; 359(8):821-32. PubMed ID: 18716299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human papillomavirus vaccines. WHO position paper.
    Wkly Epidemiol Rec; 2009 Apr; 84(15):118-31. PubMed ID: 19360985
    [No Abstract]   [Full Text] [Related]  

  • 12. The quadrivalent human papillomavirus vaccine.
    Wheat A
    Med Health R I; 2008 Dec; 91(12):387-9. PubMed ID: 19170317
    [No Abstract]   [Full Text] [Related]  

  • 13. No evidence for cross-protection of the HPV-16/18 vaccine against HPV-6/11 positivity in female STI clinic visitors.
    Woestenberg PJ; King AJ; van der Sande MA; Donken R; Leussink S; van der Klis FR; Hoebe CJ; Bogaards JA; van Benthem BH; ;
    J Infect; 2017 Apr; 74(4):393-400. PubMed ID: 28126492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A case for immunization of human papillomavirus (HPV) 6/11-infected pregnant women with the quadrivalent HPV vaccine to prevent juvenile-onset laryngeal papilloma.